Zura Bio Limited announced that it will expand its Board membership to ten, which includes Mr. Lisicki?s role as a Director of the Board. Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer. Robert Lisicki is an experienced executive leader with a career spanning 30 years in the biopharmaceutical industry.

He recently served as President and Chief Operating Officer of Zura Bio and has been serving on the boards of Adiso Therapeutics and Cadrenal Therapeutics Inc. since October 2023 and July 2023, respectively. He served as the Chief Commercial Officer at Arena Pharmaceuticals from October 2018 to March 2022, a prominent biopharmaceutical company acquired by Pfizer for $6.7 billion in 2022. At Arena, Mr. Lisicki had accountability for building the company?s global commercial infrastructure and contributed to its mergers and acquisitions activities totaling nearly $8 billion.

Prior to Arena, Mr. Lisicki served as Vice President and General Manager of Inflammation and Cardiovascular at Regeneron Pharmaceuticals. In this dual role, he led both commercial and developmental initiatives. His career also includes senior leadership roles as CEO and Board Member, InCarda Therapeutics; CCO, Daiichi Sankyo Inc.; and VP, Amgen, with his initial experience in sales and marketing at The Janssen Pharmaceutical Companies of Johnson & Johnson.

He holds a Bachelor of Science degree in Finance and Economics from the State University of New York, Albany, New York.